skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.10e (Release date: 2017-10-30)
SearchBox Top
SearchBox Bottom
Orteronel (Code C90582)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Orteronel

Definition: An orally bioavailable non-steroidal androgen synthesis inhibitor of steroid 17alpha-monooxygenase (17,20 lyase) with potential antiandrogen activity. TAK-700 binds to and inhibits the steroid 17alpha-monooxygenase in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1 (P450C17), localized to the endoplasmic reticulum (ER), exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces steroidal hormones, such as progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.

Display Name: Orteronel

Label: Orteronel

NCI Thesaurus Code: C90582 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2983781  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Androgen Synthesis Inhibitor TAK-700
CYP17A1 Lyase Inhibitor TAK-700

External Source Codes: 
CAS Registry Number 566939-85-3 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 583018
PDQ Open Trial Search ID 583018 (check for NCI PDQ open clinical trial info)
UMLS CUI C2983781

Other Properties:
     Name Value (qualifiers indented underneath)
code C90582
Contributing_Source CTRP
Contributing_Source FDA
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom